(Q35861732)

10 August 2017

1 reference

title

Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination (English)

1 reference

10 August 2017

Philippe Beutels

1

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

22

1 reference

10 August 2017

issue

25-26

1 reference

10 August 2017

page(s)

3312-3322

1 reference

Medical journals: evidence of bias against the diseases of poverty.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Medical journals and pharmaceutical companies: uneasy bedfellows.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

A reappraisal of economic evaluation of pharmaceuticals. Science or marketing?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Making economic evaluations respectable

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Evaluation of conflict of interest in economic analyses of new drugs used in oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Scope and impact of financial conflicts of interest in biomedical research: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Conflict of interest in industry-sponsored economic evaluations: real or imagined?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Methodological issues and new developments in the economic evaluation of vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Are economic evaluations of vaccines useful to decision-makers? Case study of Haemophilus influenzae type b vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

The cost-effectiveness of routine childhood varicella vaccination in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Economic evaluations of varicella vaccination programmes: a review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Hepatitis B vaccine -- do we need boosters?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: another view of the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Costs, effects and C/E-ratios alongside a clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Re: Hutton J, Brown R. Use of economic evaluation in decision-making: what needs to change? (Editorial) Value Health 2002;5:65-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Development and validation of a grading system for the quality of cost-effectiveness studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Impact of the pneumococcal conjugate vaccine on otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

Epidemiological and economic burden of pneumococcal diseases in Canadian children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.001

10.1016/J.VACCINE.2004.03.001

7 January 2021

Identifiers

DOI

1 reference

10 August 2017

1 reference